Five years of PCSK9i - Lessons from practice: Which patients benefit most?

10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

Video navigation menu

Efficacy of PCSK9-inhibition 00:32
Do we still need PCSK9-inhibition for lowering CV risk 01:01
Lessons from 5 year's practice 03:15
Who needs PCSK9-inhibition the most? 05:54
Changing landscape in high CV-risk patients 07:54

Educational information

This presentation by Prof. Erik Stroes, MD was part of the EBAC-accredited symposium "PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities" held during the virtual ESC Congress 2020.

Faculty

Prof. Erik Stroes, MD - Professor of Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Sanofi and Amgen.

Click here for the slides of the presentation Click here for the meeting report

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.